<DOC>
	<DOCNO>NCT00514696</DOCNO>
	<brief_summary>The purpose study evaluate safety GCS-100 biologic activity GCS-100 subject chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Study Safety GCS-100 Subjects With Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>The primary objective study evaluate safety GCS-100 , effect GCS-100 marker apoptosis subject chronic lymphocytic leukemia . The secondary objective study evaluate effect GCS-100 peripheral blood leukocyte count subject chronic lymphocytic leukemia .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Eligible subject must meet following criterion : 1 . Subject capable understand purpose risk study able provide write Informed Consent . 2 . Subject male female , age least 18 year . 3 . Subject diagnose chronic lymphocytic leukemia . 4 . Subject Stage II high , chronic lymphocytic leukemia currently require therapy due severity disease symptom and/or presence increase anemia and/or increase splenomegaly . 5 . Subject receive 2 few prior therapy his/her chronic lymphocytic leukemia . 6 . Subject currently require blood transfusion . 7 . Subject 's peripheral blood leukocyte count &gt; 10,000 cells/mm3 . 8 . Subject 's Karnofsky performance status &gt; 60 % . 9 . Subject 's life expectancy least 3 month . 10 . Female subject childbearing potential ( i.e. , woman surgically sterilize postmenopausal least 1 year ) , male subject partner childbearing potential , must agree use medically acceptable method contraception throughout entire study period . 11 . Subject willing able comply prescribe treatment protocol evaluation . Subjects ineligible study participation meet follow criterion : 1 . Subject receive biologic therapy and/or chemotherapy may active chronic lymphocytic leukemia within 4 week prior Study Day 1 . 2 . Subject anticipated require steroid therapy within next 21 day . 3 . Subject receive investigational ( i.e. , experimental ) therapy within 4 week prior Study Day 1 . 4 . Subject 's clinical laboratory value meet follow criterion within 7 day prior Study Day 1 : Platelet count &lt; 25,000 cells/mm3 Absolute neutrophil count &lt; 500 cells/mm3 Hemoglobin &lt; 8.0 g/dL autoimmune hemolytic component subject 's anemia AST and/or ALT &gt; 2.5 X upper limit normal Total bilirubin &gt; 1.5 X upper limit normal Serum creatinine &gt; 2 mg/dL 5 . Subject known history human immunodeficiency virus ( HIV ) , hepatitis B , and/or hepatitis C infection . 6 . Subject clinically relevant active infection and/or serious comorbid medical condition , recent myocardial infarction , unstable angina , difficulttocontrol congestive heart failure , uncontrolled hypertension , difficulttocontrol cardiac arrhythmia , chronic obstructive chronic restrictive pulmonary disease , cirrhosis , inflammatory bowel disease . 7 . Subject major surgery within 4 week prior Study Day 1 . 8 . Subject another malignancy within 3 year prior study entry , exception adequately treat basal cell squamous cell skin cancer , situ cervical cancer , situ breast cancer , situ prostate cancer , cancer subject diseasefree least 3 year . 9 . If female , subject pregnant breastfeeding . 10 . Subject concomitant disease condition , include laboratory abnormality , opinion Investigator could interfere conduct study could put subject unacceptable risk .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Leukemia</keyword>
	<keyword>GCS-100</keyword>
	<keyword>CLL</keyword>
</DOC>